Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01969344 · ClinicalTrials.gov registry record

Study of COPD Subgroups and Biomarkers

A clinical trial of Chronic Obstructive Pulmonary Disease and COPD, sponsored by University of North Carolina, Chapel Hill.

Active
Registry status
2,981
Enrollment target
14
Study locations

NCT01969344 is a study of Chronic Obstructive Pulmonary Disease and COPD that is active but no longer recruiting, run by University of North Carolina, Chapel Hill. The registered enrollment target is 2,981 participants, above the 1,719-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (73% higher). The trial reports 14 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01969344, a study of Chronic Obstructive Pulmonary Disease and COPD, is active but no longer recruiting, sponsored by University of North Carolina, Chapel Hill.

ACTIVE NOT RECRUITING
Registry status
2,981 participants
Enrollment target
14
Study locations

Study Summary

SPIROMICS I, SPIROMICS II, and SPIROMICS III are longitudinal observational studies of Chronic Obstructive Pulmonary Disease (COPD) cohort. SPIROMICS I had two primary aims: (1) To find groups of patients with COPD who share certain characteristics; (2) To find new ways of measuring whether or not COPD is getting worse and to provide new ways of testing whether a new treatment is working. SPIROMICS II had three primary aims: (1) To define the natural history of "smokers with symptoms despite preserved spirometry" and characterize the airway mucus abnormalities underlying this condition; (2) To determine the radiographic precursor lesion(s) for emphysema and identify the molecular phenotypes underlying airway disease and emphysema; (3) To advance understanding of the biology of COPD exacerbations through analysis of predisposing baseline phenotypes, exacerbation triggers and host inflammatory response. SPIROMICS III has three primary aims: (1) To identify the main forms of smoking-related airway disease that are caused by pathological airway mucus, their biological underpinnings, and their physiological significance; (2) To identify longitudinal trajectories in established and novel CT measures of emphysema, test how they predict COPD progression, and define their underlying biology; (3) To identify environmental and social determinants of health that impact disease severity and progression and their influence on lung structure, biology, and health disparities in COPD.

Study Locations (14)

California

  • University of California at Los Angeles - Los Angeles
  • University of California at San Francisco - San Francisco

New York

  • Weill Cornell Medicine - New York
  • Columbia University - New York

Alabama

  • University of Alabama at Birmingham - Birmingham

Arizona

  • Mayo Clinic Arizona - Scottsdale

Colorado

  • National Jewish Health - Denver

Illinois

  • University of Illinois at Chicago - Chicago

Iowa

  • University of Iowa - Iowa City

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 2,981 participants
Start Date 2010-11
Est. Completion 2031-06-17

What the Registry Record Tells You About NCT01969344

The ClinicalTrials.gov registry entry for NCT01969344 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 2,981 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,719-participant average among 86 other Chronic Obstructive Pulmonary Disease trials with a reported enrollment target (73% higher). The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Chronic Obstructive Pulmonary Disease appearing as the primary indexed condition, and to 0 interventions.

NCT01969344 reports 14 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Alabama.

Frequently Asked Questions

What is clinical trial NCT01969344 about?

NCT01969344 is a clinical study titled "Study of COPD Subgroups and Biomarkers". SPIROMICS I, SPIROMICS II, and SPIROMICS III are longitudinal observational studies of Chronic Obstructive Pulmonary Disease (COPD) cohort. SPIROMICS I had two primary aims: (1) To find groups of patients with COPD who share certain characteristics; (2) To find new ways of measuring whether or not ...

What is the current status of trial NCT01969344?

This trial is currently active not recruiting. The enrollment target is 2,981 participants. The study started on 2010-11. Estimated completion is 2031-06-17.

What conditions does trial NCT01969344 study?

This clinical trial studies the following conditions: Chronic Obstructive Pulmonary Disease, COPD, Emphysema, Chronic Bronchitis.

Who is sponsoring clinical trial NCT01969344?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01969344 being conducted?

This trial has 14 study locations across Alabama, Arizona, California, Colorado, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Chronic Obstructive Pulmonary Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.